Rituximab as treatment for minimal residual disease in hairy cell leukaemia

European Journal of Haematology

Volumn 73, Issue 6, 2004, Pages 412-417

  Cervetti, Giulia ^a   Galimberti, Sara ^a   Andreazzeli, Francesca ^a   Fazzi, Rita ^a   Cecconi, Nadia ^a   Caracciolo, Francesco ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cladribrine; Hairy cell leukaemia; Minimal residual disease; Rituximab

Indexed keywords

ACICLOVIR; CD20 ANTIBODY; CLADRIBINE; COTRIMOXAZOLE; DIPHENHYDRAMINE; FLUCONAZOLE; PARACETAMOL; PURINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; ERADICATION THERAPY; FEVER; HAIRY CELL LEUKEMIA; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; INFECTION; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CLADRIBINE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPOTENSION; IMMUNIZATION, PASSIVE; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 9444254651     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00325.x     Document Type: Article

References (35)

1. JANSEN J, HERMANS J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981;47:2066-2076.
2. WORMAN CP, CATOVSKY D, BEVAN PC, CAMBA L, JOYNER M, GREEN PJ, WILLIAMS HJ, BOTTOMLEY JM, GORDON-SMITH EC, CAWLEY JC. Interferon is effective in hairy cell leukaemia. Br J Haematol 1985;1985:759-763.
3. RATAIN MJ, GOLOMB HM, VARDIMAN JW, VOKES EE, JACOBS RH, DALY K. Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Blood 1985;65:644-648.
4. RAI KR, DAVEY F, PETERSON B, SCHIFFER C, SILVER RT, OZER H, GOLOMB H, BLOOMFIELD CD. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long term follow-up results of study by Cancer and Leukemia Group B. Leukemia 1995;7:1116-1120.
5. PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
6. PIRO LD, ELLISON DJ, SAVEN A, The Scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymph 1994;13 (Suppl. 1): 121-125.
7. TALLMAN MS, HAKIMIAN D, RADEMAKER AW, ZANZIG, C, WOLLINS E, ROSE E. PETERSON LC. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow up of the Northwestern University experience. Blood 1996;88:1954-1959.
8. HOFFMAN MA, JANSON D, ROSE E, RAI KR. Treatment of hairy cell leukemia with cladribine: response, toxicity, and long-term follow-up. JCO 1997;15:1138-1142.
9. CHESON BD, SORENSEN JM, VENA DA et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. JCO 1998;16:3007-3015.
10. THOMAS DA, O'BRIEN S, BUESO-RAMOS C, FADERL S, KEATING MJ, GILES FG, CORTES J, KANTARJIAN HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-3911.
11. LAURIA F, BENFENATI D, RASPADORI D, RONDELLI D, VENTURA MA, PILERI S, SABATTINI E, POGGI S, BENNI M, TURA S. Retreatment with 2-CdA of progressed HCL patients. Leuk Lymph 1994;14 (Suppl. 1):143-145.
12. SAVEN A, BINIAN C, KOZIOL JA, PIRO LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-1926.
13. KREITMAN RJ, WILSON WH, BERGERON K, RAGGIO M, STETLER-STEVENSON M, FITZGERALD DJ, PASTAN I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-247.
14. KREITMAN RJ, PASTAN I. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haemtol 2003;16:117-133.
15. JULIUSSON G, LENKEI R, LILIEMARK J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83:3672-3681.
16. GINALDI L, DE MARTINIS M, MATUTES E, FARAHAT N, MORILLA R, CATOVSKY D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51:364-369.
17. HUH YO, KEATING MJ, SAFFER HL, JILANI I, LERNER S, ALBITAR M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001;116:437-443.
18. HOFFMAN M, AUERBACH L. Bone marrow remission of hairy cell leukaemia induced by Rituximab (anti-C20 monoclonal antibody) in a patient refractory to cladribrine. Br J Haem 2000;109:900-901.
19. HAGBERG H, LUNDHOLM L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115:609-611.
20. FILLEUL B, DELANNOY A, FERRANT A et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994;8:1153-1156.
21. WHEATON S, TALLMAN MS, HAKIMIAN D, PETERSON L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87:1556-1560.
22. MATUTES E, MEEUS P, MCLENNAN K, CATOVSKY D. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long term follow-up study. Br J Haematol 1997;98:375-383.
23. LAURIA F, LENOCI M, ANNINO L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001;86:1046-1050.
24. POLLIO F, POCALI B, PALMIERI S, MORABITO P, SCALIA G, Del Vecchio L, Ferrara F. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann Hematol 2002;81:736-738.
25. GALIMBERTI S, BRIZZI F, MAMELI M, PETRINI M An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999;23:921-929.
26. CATOVSKY D, GOLOMB HM, GOLDE DW. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukaemia. Leukemia 1997;1:405-408.
27. RITTER JH, WICK MR, ADESOKAN PN, FITZGIBBON JF, ZHU X, HUMPHREY PA. Assessment of clonality in cutaneous lymphoid infiltrates by polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangement. Am J Clin Pathol 1997;108:60-68.
28. REED TJ, REID A, WALLBERG K, O'LEARY TJ, FRIZZERA G. Determination of B-cell clonality in paraffin-embedded lymph nodes using the polymerase chain reaction. Diagn Molec Pathol 1993;2:42-49.
29. MEHRA S, MESSNER H, MINDEN M., CHAGANTI RS. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 2002;33:225-234.
30. ESTEVE J, VILLAMOR N, COLOMER D. MONTSERRAT E. Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 2002;99:1873-1874
31. LAURIA F, BOCCHIA M, MAROTTA G, RASPADORI D, ZINZANI PL, RONDELLI D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999;84:22-25
32. TOBINAI K, KOBAYASHI Y, NARABAYASHI M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998;9:527-534.
33. IACONA I, LAZZARINO M, AVANZINI MA et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monitoring 2000;22:295-301.
34. JOHNSON P, GLENNIE M. The mechanism of action of Rituximab in the elimination of tumor cells. Sem Oncol 2003;30 (Suppl. 2):3-8.
35. KURZROCK R, STROM SS, ESTEY E, O'BRIEN S, KEATING MJ, JIANG H, ADAMS T, TALPAZ M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997;15:1803-1810.